Phase III results for Arikace (Insmed) v. Tobi in Cystic Fibrosis infections
Insmed reports that its Phase III study of once-daily Arikace to treat Pseudomonas aeruginosa (Pa) in Cystic Fibrosis patients conducted at 70 sites in Europe and Canada met its primary endpoint of non-inferiority compared with twice-daily Tobi (tobramycin inhalation solution) for relative change in forced expiratory volume in one second (FEV1), measured at the end of the third treatment cycle (24 weeks) as compared to baseline.
Over the course of the study, patients treated with Arikace performed numerically worse on lung function tests compared to Tobi-treated patients, but the difference in efficacy between the two antibiotics was narrow enough to be considered equivalent statistically, Insmed said. More Arikace-treated patients reported adverse events in the study compared to patients treated with Tobi. Eleven Arikace patients reported severe side effects compared to six patients on Tobi.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)